Skip to main content
SpringerLink
Log in

Thumbs up for eltrombopag, ocriplasmin, fluocinolone

  • Guideline
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. NICE. NICE gives green light to blood disorder treatment in final draft guidance. Media Release : 13 Jun 2013. Available from: URL: http://www.nice.org.uk

  2. NICE. NICE says yes to eye condition treatment in draft guidance. Media Release : 11 Jun 2013. Available from: URL: http://www.nice.org.uk

  3. NICE. NICE says yes to treatment for eye problem in some people with diabetes in new draft guidance. Media Release : 13 Jun 2013. Available from: URL: http://www.nice.org.uk

  4. NICE. NICE consults on a new treatment for colorectal cancer. Media Release : 20 Jun 2013. Available from: URL: http://www.nice.org.uk

  5. NICE. NICE appraisal of pemetrexed maintenance treatment for lung cancer. Media Release : 12 Jun 2013. Available from: URL: http://www.nice.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thumbs up for eltrombopag, ocriplasmin, fluocinolone. PharmacoEcon Outcomes News 681, 11 (2013). https://doi.org/10.1007/s40274-013-0525-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0525-0

Search

Navigation